-+ 0.00%
-+ 0.00%
-+ 0.00%

Revenue Beat: NATCO Pharma Limited Exceeded Revenue Forecasts By 20% And Analysts Are Updating Their Estimates

Simply Wall St·11/17/2026 00:12:51
Listen to the news

NATCO Pharma Limited (NSE:NATCOPHARM) just released its latest quarterly results and things are looking bullish. Performance was better than the analysts expected, with revenues of ₹9.7b coming in20% ahead of expectations, and statutory earnings per share (EPS) of ₹11.31 exceeding forecasts by 12%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on NATCO Pharma after the latest results.

earnings-and-revenue-growth
NSEI:NATCOPHARM Earnings and Revenue Growth November 17th 2026

Taking into account the latest results, the consensus forecast from NATCO Pharma's nine analysts is for revenues of ₹33.7b in 2027. This reflects a notable 11% improvement in revenue compared to the last 12 months. Statutory per share are forecast to be ₹42.09, approximately in line with the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of ₹32.3b and earnings per share (EPS) of ₹42.24 in 2027. There doesn't appear to have been a major change in sentiment following the results, other than the small lift in revenue estimates.

Check out our latest analysis for NATCO Pharma

Even though revenue forecasts increased, there was no change to the consensus price target of ₹1,002, suggesting the analysts are focused on earnings as the driver of value creation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on NATCO Pharma, with the most bullish analyst valuing it at ₹1,240 and the most bearish at ₹712 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting NATCO Pharma's growth to accelerate, with the forecast 22% annualised growth to the end of 2027 ranking favourably alongside historical growth of 15% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 12% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect NATCO Pharma to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target held steady at ₹1,002, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple NATCO Pharma analysts - going out to 2029, and you can see them free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with NATCO Pharma , and understanding this should be part of your investment process.